Floatz logo

ucb4594

Advanced Solid Tumours

Cancer Research UKPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

29 Active assets in the Advanced Solid Tumours cohort.

Asset / SponsorPhaseRating
Ceralasertib
AstraZeneca
Phase 2BB
Pembrolizumab
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase 2B
Senaparib
Impact Therapeutics, Inc.
Phase 1/2B
Cyclophosphamide
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase 2B
Epirubicin
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase 2B

View all 50 →

Same molecule, other indications

ucb4594 is also rated in:

esophageal cancerDormant
CC
Indicative ·
47 / 100
View asset →
triple-negative breast carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
head and neck squamous cell carcinomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →